

ϕ = less than 20 ppm of an anionic species; and
at least one stabilizer for inhibiting formation of the lactam, the dosage form
exhibiting improved stability.

70. (New) The stable pharmaceutical formulation of claim 65 wherein the amino acid is
gabapentin.

71. (New) The stable pharmaceutical formulation of claim 65 further comprising one or
more adjuvants.

AI 72. (New) The stable pharmaceutical formulation of claim 65 wherein said stable
pharmaceutical formulation contains less than 2% by weight of a degradation product of the
amino acid after being maintained for 3 months at 40 degrees Centigrade and 75% relative
humidity.

73. (New) The stable pharmaceutical formulation of claim 65 wherein said stabilizer is a
liquid with a dielectric constant below 60.

REMARKS

Claims 1-64 were pending.

New claims 65-73 have been added to reflect that the invention contemplates
formulations comprising at least one amino acid, less than 20 ppm of anionic species, and at
least one stabilizer, and processes for forming such formulations. Support for new claims 65-
73 can be found throughout the specification and claims as originally filed including, for
example, in paragraph no. 42, second line; in Table 2, second row corresponding to Examples
4 & 7; in paragraph no. 45, lines 2-3; in paragraph no. 47, lines 3-6; in paragraph no. 56, lines
5-6; and in paragraph no. 58, lines 7-8.


No new matter has been added.

MPCI-0033

PATENT

Upon entry of the foregoing preliminary amendments, claims 1-73 will be pending.
Consideration and allowance of the pending claims are respectfully requested.

Respectfully submitted,


Gwilym John Owen Attwell
Registration No. 45,449

Date: September 25, 2001

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100